Health Blueprint

Back to Longevity News

News summary

Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List

Source: PR Newswire • Published: 14 Nov 2026, 03:48

Summarized by Masters of Longevity from PR Newswire.

Seven Innovent products were included or expanded on China’s 2026 NRDL, effective January 1, 2027.

Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
Key Takeaways
  • Seven Innovent drugs were added to the 2026 NRDL.
  • Mazdutide showed weight loss and glucose-lowering effects.
  • Picankibart achieved over 80% PASI 90 at week 16.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.